In high-risk patients with cancer, thromboprophylaxis with rivaroxaban did not reduce VTE events at 180 days
Journal Articles
- Overview
- Research
- Identity
- Additional Document Info
- View All
Overview
status
publication date
- June 18, 2019
has subject area
- 1103 Clinical Sciences (FoR)
- 1117 Public Health and Health Services (FoR)
- Anticoagulants (MeSH)
- Heparin, Low-Molecular-Weight (MeSH)
- Humans (MeSH)
- Neoplasms (MeSH)
- Rivaroxaban (MeSH)
- Venous Thromboembolism (MeSH)
published in
- ACP journal club Journal